Clinical Trials Logo

Apathy in Dementia clinical trials

View clinical trials related to Apathy in Dementia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06047522 Recruiting - Virtual Reality Clinical Trials

Benefit of Virtual Reality Headset Use on Apathy in Older Adults With Major Neurocognitive Disorders

APATHIE_RV
Start date: January 3, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to verify that virtual reality is tolerably compatible with apathetic pathologies in patients and residents with major neurocognitive disorders. The main questions it aims to answer are: - Does virtual reality have an impact on symptoms of apathy in the elderly? - Is virtual reality well tolerated by the elderly? Participants will benefit from a 3-session virtual reality headset program with a healthcare professional. They will have one session per week for 3 weeks. They will be observed by another professional, who will complete observation grids on apathy, engagement in activity and tolerance of the virtual reality headset. There is not a comparison group: Researchers will compare the scores before and after the intervention: the participant will be his own control.

NCT ID: NCT05561205 Recruiting - Alzheimer Disease Clinical Trials

rTMS for Apathy Clinical Trial

REACT
Start date: February 9, 2023
Phase: N/A
Study type: Interventional

Apathy is a common, early, and disabling symptom in dementias such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in AD in individuals receiving methylphenidate and individuals not receiving medication for apathy.

NCT ID: NCT04958031 Recruiting - Apathy in Dementia Clinical Trials

A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy

Start date: June 22, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether CVL-871 is safe and tolerable in patients with Dementia-Related Apathy and if CVL-871 shows changes in clinical measurements of apathy.